Skip to main content
Sirnaomics Ltd. logo

Sirnaomics Ltd. — Investor Relations & Filings

Ticker · 2257 LEI · 2549004JEEDTBC6EHW37 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-12-08 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2257

About Sirnaomics Ltd.

http://www.sirnaomics.com

Sirnaomics Ltd. is a clinical-stage RNA therapeutics biopharmaceutical company focused on discovering and developing innovative drugs for indications with significant unmet medical needs. The company's pipeline addresses a broad spectrum of therapeutic areas, including oncology, fibrosis-related diseases, skin conditions, antiviral and cardiometabolic diseases, and medical aesthetics. Sirnaomics utilizes proprietary delivery platforms, which form the foundation of its RNA-based therapeutics. These platforms include the Polypeptide Nanoparticle (PNP) system for administering mRNA vaccines and therapeutics, and the GalNAc delivery platform for systemic administration of liver-targeting RNA interference (RNAi) therapeutics. The company is recognized as the first to achieve positive Phase IIb clinical outcomes in oncology using clinical-stage RNA therapeutics.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details a specific change in the company's issued share capital resulting from a share subscription. This type of filing is a regulatory requirement for listed issuers to report changes in share capital, which falls under the 'Share Issue/Capital Change' category.
2025-12-08 English
PARTIAL COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE AND TERMINATION OF SUBSCRIPTION AGREEMENT
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Sirnaomics Ltd. regarding the partial completion of a share subscription and the termination of other subscription agreements. It details the issuance of new shares, the impact on the shareholding structure, and the use of proceeds. This falls under the category of share issuance and capital changes, as it directly reports on the issuance of new shares and changes to the company's capital structure.
2025-12-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, including share capital, share options, and other equity-related changes. Since it does not fit into specific categories like 'Share Issue' (which usually refers to a specific event announcement) or 'Director's Dealing', and serves as a recurring regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-12-03 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is a formal list of directors and their roles and functions within the board committees of Sirnaomics Ltd. This type of disclosure is a standard corporate governance requirement to inform shareholders and the public about the composition of the board and its committees. It does not report on specific financial results, share transactions, or management changes, but rather provides the current governance structure. Therefore, it falls under Governance Information.
2025-12-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange (HKEX) form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Listing Rule Chapter 19B. It details movements in authorised, issued, and treasury shares, share option schemes, RSU schemes and related confirmations. This is a mandated regulatory filing rather than an investor presentation, earnings release or annual/quarterly report. It does not announce a discrete share issue event only; instead it is a comprehensive monthly regulatory return. Therefore it best fits the fallback “Regulatory Filings” category.
2025-11-05 English
UPDATE ON IMPLEMENTATION OF REMEDIAL ACTIONS ON INTERNAL CONTROL WEAKNESSES AND DEFICIENCIES
Regulatory Filings Classification · 1% confidence The document is an announcement by Sirnaomics Ltd. under HKEX Listing Rule 13.09(2)(a) providing an update on remedial actions for internal control weaknesses. It does not present full financial results (10-K, IR), executive compensation (DEF 14A), dividend details (DIV), or similar structured filings. It is not a call transcript or an investor presentation. Instead, it is a regulatory announcement of compliance matters under exchange rules, falling into the general Regulatory Filings category (RNS).
2025-10-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.